Search
Displaying 161–170 of 1059 results for “fc 26 ps4 coins Visit Buyfc26coins.com for latest FC 26 coins news..NH7v”
-
Research News
At VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
-
UCI Stem-Cell Pioneer Poised to Launch Clinical Trial for RP Patients
Research NewsDr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.
-
Pioneering Delivery Strategies for Blinding Diseases Therapy and Inspiring Women in Science
Beacon StoriesInternational Day of Women and Girls in Science is celebrated globally to recognize the critical role women play in science, technology, engineering, and mathematics. To honor this vital day, the Foundation is thrilled to spotlight Dr. Renee Ryals, PhD, a remarkable scientist at the Casey Eye Institute, Oregon Health & Science University.
-
Dan Day - Making a Difference Now and for Future Generations
Beacon Stories“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
-
Research News
A Phase 3 trial for the treatment is planned
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Research NewsTreatment combines gene therapy and a device that generates and delivers retinal code
-
Ophthotech to Boost Development of Gene Therapy for Best Disease
Research NewsOphthotech Corporation, a biopharmaceutical company focused on the development of therapies for orphan retinal diseases and age-related macular degeneration, has announced an evolving, commercial partnership with the University of Pennsylvania and University of Florida to develop a gene therapy for Best disease caused by BEST1 mutations.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
